Results 261 to 270 of about 256,130 (281)

Engineering monoclonal antibodies

Nature, 1989
Efforts to alter the mAb component of pharmaceuticals have focused on making them more human-lIke and smaller. Ultimately, the smallest molecular recognition unit derived from antibodies may be a single complementarity region.
openaire   +2 more sources

Genetically Engineered Antibody Molecules

1989
Publisher Summary The availability of monoclonally derived hybridoma antibodies provided an infinite supply of homogeneous reagents so that laboratories around the world could use standardized procedures. However, some limitations persisted. One approach to producing hybridoma antibodies with more desirable biological effector functions or antigen ...
S L, Morrison, V T, Oi
openaire   +2 more sources

Engineered antibodies

Nature Medicine, 2003
Peter J, Hudson, Christelle, Souriau
openaire   +2 more sources

Antibody engineering

Nature Biotechnology, 2023
openaire   +2 more sources

Antibody engineering for therapeutics

Current Opinion in Structural Biology, 2003
With the acceptance of antibodies as therapeutics, a diversity of engineered antibody forms have been created to improve their efficacy, including enhancing the effector functions of full-length antibodies, delivering toxins to kill cells or cytokines in order to stimulate the immune system, and bispecific antibodies to target multiple receptors. After
openaire   +2 more sources

Genetically engineered antibodies

Immunology Today, 1985
M A, Boss, C R, Wood
openaire   +2 more sources

Engineering smart antibodies

Nature Materials, 2018
openaire   +2 more sources

Engineered antibodies

Current Opinion in Structural Biology, 1991
Cristina T. Lewis, Donald Hilvert
openaire   +1 more source

Engineered antibody therapeutics

Advanced Drug Delivery Reviews, 2006
openaire   +2 more sources

Engineering Antibodies

Journal of the Indian Institute of Science, 2018
Sujan K. Dhar, Manjula Das
openaire   +1 more source